Adaptive Optics Retinal Imaging in Inherited and Acquired Retinal Disorders (NCT05386134)
Adaptive Optics Imaging in Retinal Disorders
🩺 Plain-English Summary (8th-Grade Level)
This is a Prospective Observational study. The aim of the study is to understand the underlying photoreceptor, retinal pigment epithelium or retinal vascular aberrations in inherited and acquired retinal disorders. The study would use adaptive optics (AO) technology to assist in-vivo visualization of these retinal structures and ascertain changes from normal. Further, by using the AO imaging in patients before and after treatments, this study aims to better understand the effect of various interventions and develop AO as an outcome measure in various retinal disorders.
Who can join: Review the eligibility criteria below.
Location: The Hospital for Sick Children — Toronto, Ontario
Age range: 5 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- The Hospital for Sick Children — Toronto, Ontario
📞 Contact the Study Coordinator
Phone: (416) 813-1500
Email: ajoy.vincent@sickkids.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Genetic Disease
- Clinical Decision Support to Identify Pediatric Patients With Undiagnosed Genetic Disease — Nashville, Tennessee
- Diagnostic Odyssey: Whole Genome Sequencing (WGS) — Miami, Florida
- The Electronic Medical Records and GEnomics (eMERGE) Network Genomic Risk Assessment — Birmingham, Alabama
- Penn Medicine Biobank Return of Results Program — Philadelphia, Pennsylvania
- An Open-label, Single Center, Single Participant Study of an Experimental Antisense Oligonucleotide Treatment for TUBB4A-related Leukodystrophy — San Diego, California
- Personalized Antisense Oligonucleotide Therapy for Rare Pediatric Genetic Disease: SCN2A — San Diego, California
Explore by condition: All Genetic Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.